Key result
JTV519 normalizes mutant RyR2 channel function by enhancing calstabin2 binding.
Why the study?
Familial polymorphic ventricular tachycardia caused by RyR2 missense mutations leads to exercise-induced arrhythmias and sudden cardiac death, but the molecular mechanisms and potential treatments were unclear.
Does JTV519 normalize channel function in PKA-phosphorylated mutant RyR2 channels associated with FPVT?
Does JTV519 normalize channel function in PKA-phosphorylated mutant RyR2 channels associated with FPVT?
The experimental drug JTV519 normalizes RyR2 channel function in FPVT mutations, highlighting a potential therapeutic target for preventing exercise-induced sudden cardiac death.
BACKGROUND: Familial polymorphic ventricular tachycardia (FPVT) is characterized by exercise-induced arrhythmias and sudden cardiac death due to missense mutations in the cardiac ryanodine receptor (RyR2), an intracellular Ca2+ release channel required for excitation-contraction coupling in the heart. METHODS AND RESULTS: Three RyR2 missense mutations, P2328S, Q4201R, and V4653F, which occur in Finnish families, result in similar mortality rates of approximately 33% by age 35 years and a threshold heart rate of 130 bpm, above which exercise induces ventricular arrhythmias. Exercise activates the sympathetic nervous system, increasing cardiac performance as part of the fight-or-flight stress response. We simulated the effects of exercise on mutant RyR2 channels using protein kinase A (PKA) phosphorylation. All 3 RyR2 mutations exhibited decreased binding of calstabin2 (FKBP12.6), a subunit that stabilizes the closed state of the channel. After PKA phosphorylation, FPVT-mutant RyR2 channels showed a significant gain-of-function defect consistent with leaky Ca2+ release channels and a significant rightward shift in the half-maximal inhibitory Mg2+ concentration (IC50). Treatment with the experimental drug JTV519 enhanced binding of calstabin2 to RyR2 and normalized channel function. CONCLUSIONS: Sympathetic activation during exercise induces ventricular arrhythmias above a threshold heart rate in RyR2 mutation carriers. Simulating the downstream effects of the sympathetic activation by PKA phosphorylation of RyR2 channels containing these FPVT missense mutations produced a consistent gain-of-function defect. RyR2 function and calstabin2 depletion were rescued by JTV519, suggesting stabilization of the RyR2 channel complex may represent a molecular target for the treatment and prevention of exercise-induced arrhythmias and sudden death in these patients.
No takes yet. Share an insight, caveat, or question.
Lehnart et al. (2004) studied Familial polymorphic ventricular tachycardia (FPVT). JTV519 was evaluated on RyR2 channel function and calstabin2 binding. Treatment with the experimental drug JTV519 enhanced binding of calstabin2 to mutant RyR2 channels and normalized channel function, rescuing the gain-of-function defect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: